Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled Proof of Concept Study to Assess the Safety and Efficacy of Elezanumab in Acute Traumatic Cervical Spinal Cord Injury

NCT04295538 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT04295538
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04295538 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled Proof of Concept Study to Assess the Safety and Efficacy of Elezanumab in Acute Traumatic Cervical Spinal Cord Injury
Lead sponsor
AbbVie
Phase
Phase 2
Overall status
Completed
Start date
September 6, 2020
Completion date
January 26, 2026
Enrollment
60 (actual)
Sites
41

Conditions

As the registry lists them; a condition with its own page is linked.

spinal cord injury (sci)